SCHEMBL281636

SCHEMBL281636

CC(C)(C)c1cc(N)n(CC2CCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.39
MAPK14 Q16539 3/20 0.36
PKM P14618 1/20 0.35
CNR2 P34972 2/20 0.35
CNR1 P21554 1/20 0.35
P2RY14 Q15391 3/20 0.35
HTR2C P28335 2/20 0.33
SLC6A4 P31645 2/20 0.33
LMNA P02545 1/20 0.33
HTR2A P28223 1/20 0.33
LCK P06239 1/20 0.32
RET P07949 1/20 0.32
SRC P12931 1/20 0.32
GRM2 Q14416 1/20 0.32
GRN P28799 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL282886 0.97 MEN1 (0.44) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL4898659 0.94 KDM4E (0.41) MAPTMEN1RAB9AKMT2ANPSR1
Hydrochloric Acid SCHEMBL287358 0.92 KDM4E (0.40) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL284087 0.87 CNR2 (0.40) KDM4EMAPK14CNR2CNR1
SCHEMBL24007963 0.83 KDM4E (0.38) MEN1KMT2AKDM4EMAPK14GRN
SCHEMBL15925334 0.83 CRHR1 (0.40) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL2816044 0.81 PIK3CA (0.40) MAPTNPSR1KDM4EMAPK14CNR2
SCHEMBL25745878 0.79 CNR2 (0.47) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL27800919 0.79 P2RY14 (0.34) MAPTMEN1RAB9AKMT2ANPSR1
SCHEMBL12789844 0.79 P2RY14 (0.36) MAPTMEN1RAB9AKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212241-B1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND HOFFMANN LA ROCHE (CH) 2019-05-08 EP disclosed
US-10227308-B2 Radiolabeled cannabinoid receptor 2 ligand HOFFMANN-LA ROCHE INC. (US) 2019-03-12 US disclosed
US-10227308-B2 Radiolabeled cannabinoid receptor 2 ligand HOFFMANN-LA ROCHE INC. (US) 2019-03-12 US disclosed
EP-3212241-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND F. Hoffmann-La Roche AG (CH) 2017-09-06 EP disclosed
US-20170166534-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND HOFFMANN-LA ROCHE INC. (US) 2017-06-15 US disclosed
US-20170166534-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND HOFFMANN-LA ROCHE INC. (US) 2017-06-15 US disclosed
US-20170166534-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND HOFFMANN-LA ROCHE INC. (US) 2017-06-15 US disclosed
WO-2016066534-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND F. HOFFMANN-LA ROCHE AG (CH) 2016-05-06 WO disclosed
EP-2428507-B1 Cannabinoid receptor ligands ABBVIE BAHAMAS LTD (BS) 2015-10-21 EP disclosed
EP-2896615-A1 Cannabinoid receptor ligands AbbVie Bahamas Limited (BS) 2015-07-22 EP disclosed
US-8288428-B2 Compounds as cannabinoid receptor ligands ABBOTT LABORATORIES (US) 2012-10-16 US disclosed
US-8236822-B2 Compounds as cannabinoid receptor ligands ABBOTT LABORATORIES (US) 2012-08-07 US disclosed
US-8188135-B2 Compounds as cannabinoid receptor ligands ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
EP-2428507-A2 Cannabinoid receptor ligands Abbott Laboratories (US) 2012-03-14 EP disclosed
US-20100249086-A1 Compounds As Cannabinoid Receptor Ligands ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
US-20100249087-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20100069349-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
EP-1820504-A1 IMINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 MAPT 4160/4885MEN1 761/4885RAB9A 841/4885
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R MAPT 3688/4885MEN1 2912/4885RAB9A 915/4885
US-20100069349-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R MAPT 3688/4885MEN1 2912/4885RAB9A 915/4885
US-10227308-B2 Radiolabeled cannabinoid receptor 2 ligand CNR1, CNR2, GPR174 MAPT 3573/4885MEN1 1177/4885RAB9A 1001/4885
US-20100249087-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 MAPT 2781/4885MEN1 2509/4885RAB9A 584/4885
US-20100249086-A1 Compounds As Cannabinoid Receptor Ligands CNR1, CNR2, GPR18 MAPT 2104/4885MEN1 1834/4885RAB9A 728/4885
US-20170166534-A1 RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND CNR1, CNR2, GPR174 MAPT 3573/4885MEN1 1177/4885RAB9A 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.